O	0	1	A
O	2	12	Randomized
O	13	18	Trial
O	19	29	Evaluating
B-intervention	30	42	Bioimpedance
I-intervention	43	55	Spectroscopy
O	56	62	Versus
B-control	63	67	Tape
I-control	68	79	Measurement
O	80	83	for
O	84	87	the
O	88	98	Prevention
O	99	101	of
B-condition	102	112	Lymphedema
O	113	122	Following
O	123	132	Treatment
O	133	136	for
O	137	143	Breast
O	144	150	Cancer
O	150	151	:
O	152	159	Interim
O	160	168	Analysis
O	168	169	.

O	170	176	Breast
O	177	183	cancer
O	183	184	-
O	184	191	related
O	192	202	lymphedema
O	203	204	(
O	204	208	BCRL
O	208	209	)
O	210	220	represents
O	221	222	a
O	223	228	major
O	229	235	source
O	236	238	of
O	239	248	morbidity
O	249	254	among
O	255	261	breast
O	262	268	cancer
O	269	278	survivors
O	278	279	.

O	280	290	Increasing
O	291	295	data
O	296	303	support
O	304	309	early
O	310	319	detection
O	320	322	of
O	323	334	subclinical
O	335	339	BCRL
O	340	348	followed
O	349	351	by
O	352	357	early
O	358	370	intervention
O	370	371	.

O	372	373	A
O	374	384	randomized
O	385	395	controlled
O	396	401	trial
O	402	404	is
O	405	410	being
O	411	420	conducted
O	421	430	comparing
O	431	441	lymphedema
O	442	453	progression
O	454	459	rates
O	460	465	using
O	466	472	volume
O	473	485	measurements
O	486	496	calculated
O	497	501	from
O	502	505	the
O	506	519	circumference
O	520	525	using
O	526	527	a
O	528	532	tape
O	533	540	measure
O	541	542	(
O	542	544	TM
O	544	545	)
O	546	548	or
O	549	561	bioimpedance
O	562	574	spectroscopy
O	575	576	(
O	576	579	BIS
O	579	580	)
O	580	581	.

O	582	590	Patients
O	591	595	were
O	596	604	enrolled
O	605	608	and
O	609	619	randomized
O	620	622	to
O	623	629	either
O	630	632	TM
O	633	635	or
O	636	639	BIS
O	640	652	surveillance
O	652	653	.

B-eligibility	654	662	Patients
I-eligibility	663	672	requiring
I-eligibility	673	678	early
I-eligibility	679	691	intervention
O	692	696	were
O	697	707	prescribed
O	708	709	a
O	710	721	compression
O	722	728	sleeve
O	729	732	and
O	733	741	gauntlet
O	742	745	for
O	746	747	4
O	748	753	weeks
O	754	757	and
O	758	762	then
O	763	765	re
O	765	766	-
O	766	775	evaluated
O	775	776	.

O	777	780	The
O	781	788	primary
O	789	797	endpoint
O	798	800	of
O	801	804	the
O	805	810	trial
O	811	814	was
O	815	818	the
B-outcome-Measure	819	823	rate
I-outcome-Measure	824	826	of
I-outcome-Measure	827	838	progression
I-outcome-Measure	839	841	to
I-outcome-Measure	842	850	clinical
I-outcome-Measure	851	861	lymphedema
I-outcome-Measure	862	871	requiring
I-outcome-Measure	872	879	complex
I-outcome-Measure	880	892	decongestive
I-outcome-Measure	893	906	physiotherapy
I-outcome-Measure	907	908	(
I-outcome-Measure	908	911	CDP
I-outcome-Measure	911	912	)
O	912	913	,
O	914	918	with
O	919	930	progression
O	931	938	defined
O	939	941	as
O	942	943	a
O	944	946	TM
O	947	953	volume
O	954	960	change
O	961	963	in
O	964	967	the
O	968	970	at
O	970	971	-
O	971	975	risk
O	976	979	arm
O	980	981	≥
O	982	984	10
O	984	985	%
O	986	991	above
O	992	995	the
O	996	1007	presurgical
O	1008	1016	baseline
O	1016	1017	.

O	1018	1022	This
O	1023	1035	prespecified
O	1036	1043	interim
O	1044	1052	analysis
O	1053	1056	was
O	1057	1066	performed
O	1067	1071	when
O	1072	1074	at
O	1075	1080	least
O	1081	1084	500
O	1085	1090	trial
O	1091	1103	participants
O	1104	1107	had
O	1108	1109	≥
O	1110	1112	12
O	1113	1119	months
O	1120	1122	of
O	1123	1129	follow
O	1129	1130	-
O	1130	1132	up
O	1132	1133	.

O	1134	1135	A
O	1136	1141	total
O	1142	1144	of
B-total-participants	1145	1148	508
O	1149	1157	patients
O	1158	1162	were
O	1163	1171	included
O	1172	1174	in
O	1175	1179	this
O	1180	1188	analysis
O	1188	1189	,
O	1190	1194	with
O	1195	1198	109
O	1199	1200	(
O	1200	1202	21
O	1202	1203	.
O	1203	1204	9
O	1204	1205	%
O	1205	1206	)
O	1207	1215	patients
O	1216	1226	triggering
O	1227	1239	prethreshold
O	1240	1253	interventions
O	1253	1254	.

O	1255	1263	Compared
O	1264	1268	with
O	1269	1271	TM
O	1271	1272	,
O	1273	1276	BIS
O	1277	1280	had
O	1281	1282	a
O	1283	1288	lower
B-outcome	1289	1293	rate
I-outcome	1294	1296	of
I-outcome	1297	1304	trigger
O	1305	1306	(
B-iv-bin-percent	1306	1308	15
I-iv-bin-percent	1308	1309	.
I-iv-bin-percent	1309	1310	8
I-iv-bin-percent	1310	1311	%
O	1312	1314	vs
O	1314	1315	.
B-cv-bin-percent	1316	1318	28
I-cv-bin-percent	1318	1319	.
I-cv-bin-percent	1319	1320	5
I-cv-bin-percent	1320	1321	%
O	1321	1322	,
O	1323	1324	p
O	1325	1326	<
O	1327	1328	0
O	1328	1329	.
O	1329	1332	001
O	1332	1333	)
O	1334	1337	and
O	1338	1344	longer
B-outcome	1345	1350	times
I-outcome	1351	1353	to
I-outcome	1354	1361	trigger
O	1362	1363	(
B-iv-cont-median	1363	1364	9
I-iv-cont-median	1364	1365	.
I-iv-cont-median	1365	1366	5
O	1367	1369	vs
O	1369	1370	.
B-cv-cont-median	1371	1372	2
I-cv-cont-median	1372	1373	.
I-cv-cont-median	1373	1374	8
I-cv-cont-median	1375	1381	months
O	1381	1382	,
O	1383	1384	p
O	1385	1386	=
O	1387	1388	0
O	1388	1389	.
O	1389	1392	002
O	1392	1393	)
O	1393	1394	.

O	1395	1401	Twelve
B-outcome	1402	1412	triggering
I-outcome	1413	1421	patients
I-outcome	1422	1432	progressed
I-outcome	1433	1435	to
I-outcome	1436	1439	CDP
O	1440	1441	(
B-cv-bin-abs	1441	1443	10
O	1444	1446	in
O	1447	1450	the
O	1451	1453	TM
O	1454	1459	group
O	1460	1461	[
B-cv-bin-percent	1461	1463	14
I-cv-bin-percent	1463	1464	.
I-cv-bin-percent	1464	1465	7
I-cv-bin-percent	1465	1466	%
O	1466	1467	]
O	1468	1471	and
B-iv-bin-abs	1472	1473	2
O	1474	1476	in
O	1477	1480	the
O	1481	1484	BIS
O	1485	1490	group
O	1491	1492	[
B-iv-bin-percent	1492	1493	4
I-iv-bin-percent	1493	1494	.
I-iv-bin-percent	1494	1495	9
I-iv-bin-percent	1495	1496	%
O	1496	1497	]
O	1497	1498	)
O	1498	1499	,
O	1500	1512	representing
O	1513	1514	a
O	1515	1517	67
O	1517	1518	%
O	1519	1527	relative
O	1528	1537	reduction
O	1538	1541	and
O	1542	1543	a
O	1544	1545	9
O	1545	1546	.
O	1546	1547	8
O	1547	1548	%
O	1549	1557	absolute
O	1558	1567	reduction
O	1568	1569	(
O	1569	1570	p
O	1571	1572	=
O	1573	1574	0
O	1574	1575	.
O	1575	1578	130
O	1578	1579	)
O	1579	1580	.

O	1581	1588	Interim
O	1589	1596	results
O	1597	1609	demonstrated
O	1610	1614	that
O	1615	1619	post
O	1619	1620	-
O	1620	1629	treatment
O	1630	1642	surveillance
O	1643	1647	with
O	1648	1651	BIS
O	1652	1659	reduced
O	1660	1663	the
O	1664	1672	absolute
O	1673	1678	rates
O	1679	1681	of
O	1682	1693	progression
O	1694	1696	of
O	1697	1701	BCRL
O	1702	1711	requiring
O	1712	1715	CDP
O	1716	1718	by
O	1719	1732	approximately
O	1733	1735	10
O	1735	1736	%
O	1736	1737	,
O	1738	1739	a
O	1740	1750	clinically
O	1751	1761	meaningful
O	1762	1773	improvement
O	1773	1774	.

O	1775	1780	These
O	1781	1788	results
O	1789	1796	support
O	1797	1800	the
O	1801	1808	concept
O	1809	1811	of
O	1812	1816	post
O	1816	1817	-
O	1817	1826	treatment
O	1827	1839	surveillance
O	1840	1844	with
O	1845	1848	BIS
O	1849	1851	to
O	1852	1858	detect
O	1859	1870	subclinical
O	1871	1875	BCRL
O	1876	1879	and
O	1880	1888	initiate
O	1889	1894	early
O	1895	1907	intervention
O	1907	1908	.
